Full-Time

Medical Director

Atlanta

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Senior

Atlanta, GA, USA

Must be eligible for Georgia medical license.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD, eligible for Georgia medical license
  • Board-certified in Anatomic Pathology and Molecular Genetic Pathology
  • Hold or be eligible to hold a NYS CoQ license in genetic testing
  • Significant experience in establishing and/or maintaining CAP/CLIA laboratories
  • Clinical experience with next generation sequencing
  • Excellent managerial, organizational, reporting and communication skills
Responsibilities
  • Planning, organizing, and directing the clinical laboratory department, including molecular testing and IHC
  • Provide cross-functional leadership and medical subject matter expertise
  • Ensure that services are of the highest quality, are cost contained, are medically useful and accurate, and are carried out in an expeditious manner
  • Participate in all relevant managerial decisions and guide the operations of the laboratory ranging from the selection of staff, choice of methods, purchase of equipment, quality assurance, quality control and safety
  • Ensure regulatory compliance (CLIA/CAP, NYSDOH)
  • Ensure all QC and SOPs are routinely developed, evaluated and up to date
  • Responsible for molecular clinical report review and signout, and pathology slide review
  • Collaborate with multi-disciplinary team focused on answering key medical questions

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

15%

2 year growth

36%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.

Help us improve and share your feedback! Did you find this helpful?